Breast Cancer Research » Potential

Cancer-related pathways reveal potential treatment target for congenital heart disease

Sun, 27 Feb 2011 23:20:59 +0000

Cancer-related pathways reveal potential treatment target for congenital heart disease
(PhysOrg.com) — Cross-disciplinary teams of scientists studying genetic pathways that are mutated in many forms of cancer, but which also cause certain forms of congenital heart disease, including hypertrophic cardiomyopathy (HCM), have introduced these mutations into mice and successfully treated HCM in the lab.

New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel’s Seliciclib in Treating Breast Cancer …

Mon, 10 Jan 2011 02:48:00 +0000

New Study in Clinical Cancer Research Demonstrates Potential for Cyclacel’s Seliciclib in Treating Breast Cancer …
BERKELEY HEIGHTS, N.J. — Cyclacel Pharmaceuticals, Inc. today announced that a newly published study demonstrates that the company’s seliciclib , an orally available inhibitor of multiple cyclin-dependent kinases , reversed resistance to the aromatase inhibitor letrozole and killed hormone receptor positive breast cancer cells that had become insensitive to the effects of letrozole. The new …

Potential therapeutic target across a range of cancer types found

Mon, 25 Oct 2010 00:39:02 +0000

Potential therapeutic target across a range of cancer types found
London, Oct 21 : Researchers have found a common link among several malignant tumor types in all grades of cancer.

Researchers Find Potential Therapeutic Target Across a Range of Cancer Types

Sun, 24 Oct 2010 00:35:29 +0000

Researchers Find Potential Therapeutic Target Across a Range of Cancer Types
Researchers from Mount Sinai School of Medicine, in collaboration with investigators of the National Institute of Health and Medical Research (INSERM) of France led by Nicolae Ghinea, PhD, have found a common link among several malignant tumor types in all grades of cancer. This breakthrough may ultimately provide a new diagnostic or therapeutic target to detect cancer early or stop tumor growth …

Adiponectin Shows Potential In Blocking Obesity-Related Carcinogenesis

Tue, 19 Oct 2010 23:40:11 +0000

Adiponectin Shows Potential In Blocking Obesity-Related Carcinogenesis
Protein hormone inhibits leptin-induced migration of liver cancer cells A research team from Emory University School of Medicine investigated the role between adiponectin and leptin in obesity-related carcinogenesis. Their findings, published in the November issue of Hepatology, suggest that the protein hormone adiponectin has potential for inhibiting the oncogenic actions of leptin, namely in …

FDA denies accelerated approval for ImmunoGen, Genentech potential breast cancer treatment

Tue, 31 Aug 2010 23:50:52 +0000

FDA denies accelerated approval for ImmunoGen, Genentech potential breast cancer treatment
WALTHAM, Mass. – Federal regulators have ruled that a potential breast cancer treatment from ImmunoGen failed to meet the standard for accelerated approval, the company said Friday.

Medicaid Help a Potential Lifeline for State Breast Cancer Programs

Sat, 14 Aug 2010 23:44:38 +0000

Medicaid Help a Potential Lifeline for State Breast Cancer Programs
WASHINGTON, D.C.—-The Susan G. Komen for the Cure® Advocacy Alliance thanked Congress and the Administration for a six-month extension of enhanced federal funding for Medicaid, which was signed into law Tuesday night.

Provectus Pharmaceuticals to Use Numoda’s TruPoints System to Facilitate Transactions with Potential Licensing …

Fri, 30 Jul 2010 00:38:42 +0000

Provectus Pharmaceuticals to Use Numoda’s TruPoints System to Facilitate Transactions with Potential Licensing …
KNOXVILLE, Tenn.—-Provectus Pharmaceuticals, Inc. , a development-stage oncology and dermatology biopharmaceutical company, has signed an agreement with Numoda Capital Innovations LLC to license its TruPoints® strategic partnering platform.

Shares jump for potential targets of Sanofi deal

Mon, 05 Jul 2010 23:39:46 +0000

Shares jump for potential targets of Sanofi deal
FILE – In this May 12, 2009 file photo, Sanofi CEO Chris Viehbacher, delivers his speech during the launch of Sanofi Pasteur’s new plant. Rumors French pharmaceutical giant Sanofi-Aventis SA is chasing a big U.S. acquisition Friday, July 2, 2010, have driven up shares of companies investors think might be a target.(AP Photo/Laurent Cipriani, file)

A Potential new Breakthrough for Breast Cancer

Sat, 03 Jul 2010 23:43:23 +0000

Get the facts about Zometa, a new bone loss drug that may decrease your chances at breast cancer recurrence. Not yet used by doctors, Zometa is still undergoing clinical trials and may cause certain side effects.